Trimetazidine Use in Parkinson’s Disease: Is It a Resolved Problem?

Trimetazidine (TMZ), an antianginal drug, can worsen the symptoms of movement disorders, therefore, the European Medicines Agency (EMA) recommended avoiding the use of this drug in Parkinson’s disease (PD). We investigated the impact of this recommendation on the observed trend of TMZ use in PD in H...

Descripción completa

Detalles Bibliográficos
Autores principales: Pintér, Dávid, Bereczki, Dániel, Ajtay, András, Oberfrank, Ferenc, Janszky, József, Kovács, Norbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society for Neuroscience 2021
Materias:
Research Article: New Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143021/
https://www.ncbi.nlm.nih.gov/pubmed/33863783
http://dx.doi.org/10.1523/ENEURO.0452-20.2021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143021/
https://www.ncbi.nlm.nih.gov/pubmed/33863783
http://dx.doi.org/10.1523/ENEURO.0452-20.2021

Ejemplares similares